Tesamorelin Randomized Trials: Arms, Controls, and Reported Protocol Details

Disclosure: Peptide Bio Index is affiliated with SourcePoint Research and may earn from qualifying purchases or affiliate links.

This focused deep dive summarizes what the provided reviewed sources report about randomized trial arms, controls, and protocol details for tesamorelin (Egrifta). The available excerpts are predominantly reviews and a brief drug news item; primary randomized trial publications or trial-registry records were not included among the reviewed excerpts.

Regulatory status and clinical context reported in the reviewed sources

The reviewed sources identify tesamorelin (marketed as Egrifta) as a growth hormone–releasing factor analogue that received US Food and Drug Administration approval in November 2010 for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy (regulatory/news summary). ^[S4]

Narrative reviews included in the reviewed set list tesamorelin/Egrifta among approved therapeutic peptides and note its indication for HIV-associated lipodystrophy in the clinical therapeutics landscape. ^{[S1] [S3]}

Availability of randomized trial arm and control details in the reviewed excerpts

Within the provided reviewed excerpts (narrative reviews and a drug news item), explicit randomized trial-arm descriptions, control types, or detailed trial-arm nomenclature are not reported; the documents are summary-level and do not reproduce primary randomized trial protocols or arms/controls lists. ^{[S1] [S2] [S3] [S4]}

Reported protocol elements (amount, route, frequency, duration) in the reviewed sources

Amount: not reported in the reviewed source. ^{[S1] [S2] [S3] [S4]}

Route: not reported in the reviewed source. ^{[S1] [S2] [S3] [S4]}

Frequency: not reported in the reviewed source. ^{[S1] [S2] [S3] [S4]}

Duration: not reported in the reviewed source. ^{[S1] [S2] [S3] [S4]}

Types of evidence present in the reviewed set and what they permit

The reviewed records are primarily narrative reviews focused on therapeutic peptides and on safety/efficacy summaries in sports or orthopaedic contexts; these reviews list tesamorelin among peptides of interest but do not reproduce primary randomized trial protocols or detailed arm/control schemata. ^{[S1] [S2] [S3]}

A brief drug-news item in the reviewed set documents the FDA approval milestone for tesamorelin but does not include granular randomized trial arm or protocol details. ^[S4]

Implications for compiling randomized-trial protocol details

Because the provided excerpts lack primary randomized-trial reports or registry entries, assembling an accurate table of trial arms, comparator types, and precise protocol elements will require retrieval of original trial publications, ClinicalTrials.gov records, sponsor regulatory submissions, or the Egrifta product label that cite the underlying trials. ^{[S1] [S3] [S4]}

Reported study-design details from cited sources

The following table summarizes protocol details reported in cited studies. These details are provided as literature context only and are not recommendations or instructions.

The reviewed sources did not provide enough protocol detail to build a complete source-labeled protocol table.

Limitations and research gaps

• Reviewed source set contains narrative reviews and a short drug-news item; no full primary randomized controlled trial reports or trial-registry records were included in the provided excerpts.
• Key protocol elements commonly requested for protocol-synthesis (dose amounts, administration route, dosing frequency, treatment duration, explicit arm definitions, and control descriptions) are not present in the reviewed excerpts and therefore could not be extracted.
• Because the evidence available here is summary-level, source_limited is set to true to reflect that the coverage is constrained by the provided records and cannot substitute for primary trial documents.

Documentation checklist

• Search PubMed for primary randomized controlled trials of tesamorelin and retrieve full-text publications.
• Check ClinicalTrials.gov and other trial registries for registered randomized trials and their posted protocols.
• Obtain the FDA product label (Egrifta) and sponsor regulatory submissions for prespecified clinical trial designs and endpoints.
• If extracting arms/controls, record explicit trial arm names, comparator types (placebo, active comparator, dose-ranging), and randomization schema as stated in primary sources.
• When protocol fields are missing in reviews or news items, locate original trial reports or registry entries before recording amounts, routes, frequencies, or durations.

Related research supplies

• Egrifta (tesamorelin) manufacturer prescribing information / product label (for reference and protocol citations)
• Clinical trial registry search log (template) for tracking trial identifiers and protocol links
• Protocol extraction spreadsheet or database template
• Temperature-controlled storage log sheets (documentation for handling investigational products)

Sources and references

1. [S1] Mayfield CK, Bolia IK, Feingold CL, Lin EH, Liu JN, Rick Hatch GF. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.. The American journal of sports medicine. 2026. PMID: 41476424. DOI: 10.1177/03635465251357593
2. [S2] Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.. Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews. 2026. PMID: 41490200. DOI: 10.5435/JAAOSGlobal-D-25-00236
3. [S3] Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.. Sports medicine (Auckland, N.Z.). 2026. PMID: 41966639. DOI: 10.1007/s40279-026-02437-0
4. [S4] Grunfeld C, Dritselis A, Kirkpatrick P. Tesamorelin.. Nature reviews. Drug discovery. 2011. PMID: 21283099. DOI: 10.1038/nrd3362
5. [S5] O'Neal R. Tesamorelin update.. BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation. 2010. PMID: 21591600

Peptide Bio Index is affiliated with SourcePoint Research. Articles may link to SourcePointResearch.com and third-party affiliate products. As an Amazon Associate, Peptide Bio Index earns from qualifying purchases. Content is educational and research-literature focused only and is not medical advice, dosing guidance, or a personal-use recommendation.